A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Hebei Medical University

Status: Enrolling

Conditions: Extensive Stage Small Cell Lung Cancer

Treatments: Drug: Adebrelimab + chemotherapy; Radiation: ±chest radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06323265

ARL-SCLC-001

Details and patient eligibility

About

The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age:≥18 years old;
2. Patients with extensive stage small cell lung cancer confirmed by histopathology;
3. Normal function of major organs;
4. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.

Exclusion criteria

1. Patients with drug allergy sufferers;
2. Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc;
3. History of psychiatric drugs abuse and can't quit or patients with mental disorders;
4. The researchers think inappropriate.

Trial design

50 participants in 1 patient group

Experimental

Treatment:

Radiation: ±chest radiotherapy

Drug: Adebrelimab + chemotherapy